4570 Stock Overview
Engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Immuno-Biological Laboratories Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥452.00 |
| 52 Week High | JP¥649.00 |
| 52 Week Low | JP¥358.00 |
| Beta | 0.25 |
| 1 Month Change | -9.78% |
| 3 Month Change | 1.57% |
| 1 Year Change | -1.53% |
| 3 Year Change | 27.68% |
| 5 Year Change | -34.21% |
| Change since IPO | -49.21% |
Recent News & Updates
Recent updates
There May Be Underlying Issues With The Quality Of Immuno-Biological Laboratories' (TSE:4570) Earnings
Nov 20
Immuno-Biological Laboratories (TSE:4570) Seems To Use Debt Rather Sparingly
Aug 03Investors Shouldn't Be Too Comfortable With Immuno-Biological Laboratories' (TSE:4570) Earnings
May 22We Think Immuno-Biological Laboratories (TSE:4570) Can Manage Its Debt With Ease
Feb 29Is Immuno-Biological Laboratories (TYO:4570) Using Debt In A Risky Way?
Feb 09Shareholder Returns
| 4570 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | -3.6% | -2.9% | -1.5% |
| 1Y | -1.5% | -13.7% | 13.7% |
Return vs Industry: 4570 exceeded the JP Life Sciences industry which returned -13.7% over the past year.
Return vs Market: 4570 underperformed the JP Market which returned 13.7% over the past year.
Price Volatility
| 4570 volatility | |
|---|---|
| 4570 Average Weekly Movement | 8.6% |
| Life Sciences Industry Average Movement | 5.5% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4570's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4570's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 57 | Tsutomu Seito | www.ibl-japan.co.jp |
Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; and support research services on Alzheimer’s disease, metabolic syndrome, and cancer, as well as customized services for production of customized antibodies and development of ELISA systems. It also provides LipoSEARCH, a customized services for profiling and analyzing of lipoprotein through gel-filtration high performance liquid chromatography method that can profile various clinical samples, such as tiny plasma or serum samples from both small animals and human beings for broad range of research fields including lipid metabolism, development of drugs for life-style related diseases, development of functional supplemental foods, and clinical studies.
Immuno-Biological Laboratories Co., Ltd. Fundamentals Summary
| 4570 fundamental statistics | |
|---|---|
| Market cap | JP¥4.21b |
| Earnings (TTM) | JP¥231.00m |
| Revenue (TTM) | JP¥895.00m |
18.2x
P/E Ratio4.7x
P/S RatioIs 4570 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4570 income statement (TTM) | |
|---|---|
| Revenue | JP¥895.00m |
| Cost of Revenue | JP¥315.00m |
| Gross Profit | JP¥580.00m |
| Other Expenses | JP¥349.00m |
| Earnings | JP¥231.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 10, 2025
| Earnings per share (EPS) | 24.80 |
| Gross Margin | 64.80% |
| Net Profit Margin | 25.81% |
| Debt/Equity Ratio | 14.7% |
How did 4570 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 07:26 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Immuno-Biological Laboratories Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|